The pharmacological management of oppositional behaviour, conduct problems, and Aggression in children and adolescents with Attention-deficit hyperactivity disorder, oppositional defiant disorder, and conduct disorder: A systematic review and meta-analysis. Part 2: Antipsychotics and traditional mood stabilizers

Canadian Journal of Psychiatry

Volumn 60, Issue 2, 2015, Pages 52-61

  Pringsheim, Tamara ^a,b   Hirsch, Lauren ^a   Gardner, David ^c   Gorman, Daniel A ^d  

^a UNIVERSITY OF CALGARY   (Canada)

^b Calgary Tourette and Pediatric Movement Disorders Clinic   (Canada)

^c DALHOUSIE UNIVERSITY   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

Antipsychotics; Attention deficit hyperactivity disorder; Children; Conduct disorder; Meta analysis; Mood stabilizers; Oppositional defiant disorder; Systematic review

Indexed keywords

ANTICONVULSIVE AGENT; ARIPIPRAZOLE; HALOPERIDOL; LITHIUM; LITHIUM CARBONATE; MOLINDONE; MOOD STABILIZER; NEUROLEPTIC AGENT; PLACEBO; QUETIAPINE; RISPERIDONE; THIORIDAZINE; VALPROATE SEMISODIUM; ZIPRASIDONE; TRANQUILIZER;

AGGRESSION; ATTENTION DEFICIT DISORDER; CONDUCT DISORDER; DISRUPTIVE BEHAVIOR; HUMAN; INTELLIGENCE QUOTIENT; META ANALYSIS; OPPOSITIONAL DEFIANT DISORDER; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; ADOLESCENT; ATTENTION DEFICIT AND DISRUPTIVE BEHAVIOR DISORDERS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; DRUG EFFECTS;

ADOLESCENT; AGGRESSION; ANTICONVULSANTS; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; ATTENTION DEFICIT AND DISRUPTIVE BEHAVIOR DISORDERS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; CONDUCT DISORDER; HUMANS;

EID: 84922683632     PISSN: 07067437     EISSN: 14970015     Source Type: Journal    
DOI: 10.1177/070674371506000203     Document Type: Review

References (31)

1. Brault MC, Lacourse E. Prevalence of prescribed attentiondeficit hyperactivity disorder medications and diagnosis among Canadian preschoolers and school-age children: 1994-2007. Can J Psychiatry. 2012;57(2):93-101.
2. Breton JJ, Bergeron L, Valla JP, et al. Quebec Child Mental Health Survey: prevalence of DSM-III-R mental health disorders. J Child Psychol Psychiatry. 1999;40(3):375-384.
3. Maughan B, Rowe R, Messer J, et al. Conduct disorder and oppositional defiant disorder in a national sample: developmental epidemiology. J Child Psychol Psychiatry. 2004;45(3):609-621.
4. Pingault JB, Côté SM, Lacourse E, et al. Childhood hyperacti vity, physical aggression and criminality: a 19-year prospective population-based study. PLoS ONE. 2013;8(5):e62594.
5. Klassen AF, Miller A, Fine S. Health-related quality of life in children and adolescents who have a diagnosis of attention-deficit/hyperactivity disorder. Pediatrics. 2004;114:e541.
6. Pringsheim T, Lam D, Patten S. The pharmacoepidemiology of antipsychotic medications for Canadian children and adolescents: 2005-2009. J Child Adolesc Psychopharmacol. 2011;21(6):537-543.
7. Ronsley R, Scott D, Warburton WP, et al. A population-based study of antipsychotic prescription trends in children and adolescents in British Columbia, from 1996 to 2011. Can J Psychiatry. 2013;58(6):361-369.
8. Alessi-Severini S, Biscontri RG, Collins DM, et al. Ten years of antipsychotic prescribing to children: a Canadian population-based study. Can J Psychiatry. 2012;57(1):52-58.
9. Murphy AL, Gardner DM, Cooke C, et al. Prescribing trends of antipsychotics in youth receiving income assistance: results from a retrospective population database study. BMC Psychiatry. 2013;13(1):198.
10. Pringsheim T, Lam D, Ching H, et al. Metabolic and neurological complications of second-generation antipsychotic use in children: a systematic review and meta-analysis of randomized controlled trials. Drug Saf. 2011;34(8):651-668.
11. Pringsheim T, Panagiotopoulos C, Davidson J, et al. Evidencebased recommendations for monitoring safety of secondgeneration antipsychotics in children and youth. Paediatr Child Health. 2011;16(9):581-589.
12. Pringsheim T, Hirsch L, Gardner DM, et al. The pharmacological management of oppositional behaviour, conduct problems, and aggression in children and adolescents with attentiondeficit hyperactivity disorder, oppositional defiant disorder, and conduct disorder: a systematic review and meta-analysis. Part 1: psychostimulants, alpha-2 agonists, and atomoxetine. Can J Psychiatry. 2015;60(2):42-51.
13. Snyder R, Turgay A, Aman M, et al. Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. Am Acad Child Adolesc Psychiatry. 2002;41(9):1026-1036.
14. Aman M, De Smedt G, Derivan A, et al; Risperidone Disruptive Behavior Study Group. Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry. 2002;159(8):1337-1346.
15. Buitelaar J, van der Gaag R, Cohen-Kettenis P, et al. A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities. J Clin Psychiatry. 2001;62(4):239-248.
16. Van Bellinghen M, De Troch C. Risperidone in the treatment of behavioral disturbances in children and adolescents with borderline intellectual functioning: a double-blind, placebocontrolled pilot trial. J Child Adolesc Psychopharmacol. 2001;11(1):5-13.
17. Reyes M, Buitelaar J, Toren P, et al. A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorders. Am J Psychiatry. 2006;163(3):402-410.
18. Aman M, Bukstein OG, Gadow KD, et al. What does risperidone add to stimulant and parent training for severe aggression in child attention-deficit/hyperactivity disorder? J Am Acad Child Adolesc Psychiatry. 2014;53(1):47-60.
19. Armenteros JL, Lewis JE, Davalos M. Risperidone augmentation for treatment-resistant aggression in attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007;46(5):558-565.
20. Findling RL, McNamara NK, Branicky LA, et al. A double-blind pilot study of risperidone in the treatment of conduct disorder. Am Acad Child Adolesc Psychiatry. 2000;39(4):509-516.
21. Connor DF, McLaughlin TJ, Jeffers-Terry M. Randomized controlled pilot study of quetiapine in the treatment of adolescent conduct disorder. J Child Adolescent Psychopharmacol. 2008;18(2):140-156.
22. Campbell M, Small AM, Green WH, et al. Behavioral efficacy of haloperidol and lithium carbonate. A comparison in hospitalized aggressive children with conduct disorder. Arch Gen Psychiatry. 1984;41(7):650-656.
23. Aman MG, Marks RE, Turbott SH, et al. Methylphenidate and thioridazine in the treatment of intellectually subaverage children: effects on cognitive-motor performance. J Am Acad Child Adolesc Psychiatry. 1991;30(5):816-824.
24. Rifkin A, Karajgi B, Dicker R, et al. Lithium treatment of conduct disorders in adolescents. Am J Psychiatry. 1997;154(4):554-555.
25. Malone RP, Delaney MA, Luebbert JF, et al. A double-blind placebo-controlled study of lithium in hospitalized aggressive children and adolescents with conduct disorder. Arch Gen Psychiatry. 2000;57(7):649-654.
26. Campbell M, Adams PB, Small AM, et al. Lithium in hospitalized aggressive children with conduct disorder: a double-blind and placebo-controlled study. J Am Acad Child Adolesc Psychiatry. 1995;34(4):445-453.
27. Blader JC, Schooler NR, Jensen PS, et al. Adjunctive divalproex versus placebo for children with ADHD and aggression refractory to stimulant monotherapy. Am J Psychiatry. 2009;166(12):1392-1401.
28. Donovan SJ, Stewart JW, Nunes EV, et al. Divalproex treatment for youth with explosive temper and mood lability: a double-blind, placebo-controlled crossover design. Am J Psychiatry. 2000;157(5):818-820.
29. Erratum in: Am J Psychiatry. 2000;157(6):1038.
30. Cueva JE, Overall JE, Small AM, et al. Carbamazepine in aggressive children with conduct disorder: a double-blind and placebo-controlled study. J Am Acad Child Adolesc Psychiatry. 1996;35(4):480-490.
31. Scotto Rosato N, Correll CU, Pappadopulos E, et al. Treatment of maladaptive aggression in youth: CERT guidelines II. Treatments and ongoing management. Pediatrics. 2012;129(6):e1577-e1586.